Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on March 20, 2024
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 19, 2024, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Wednesday, March 20, 2024, to discuss the results and provide a business update.
Conference Call Details: |
|
Date: |
Wednesday, March 20, 2024 |
Time: |
8:00 a.m. Eastern time |
Participant Dial-in: |
1-833-953-2434 (U.S.)
|
Replay Dial-in (Passcode 6766979): (telephonic replay through March 27, 2024) |
1-877-344-7529 (U.S.)
|
Webcast: (online replay through March 20, 2025) |
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
Jamie Webb
Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305397352/en/
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track